02069nas a2200385   4500000000100000008004100001260001300042653001000055653001100065653001600076653001200092653003000104653001100134653001100145653002300156653001200179653000900191653001600200653002600216653001300242653002200255100001200277700001300289700001300302700001200315700001700327700001600344245007500360856005100435300001100486490000700497050003200504520113300536022001401669       2007                            d  c2007 Sep10aAdult10aBrazil10aClofazimine10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aRetrospective Studies10aRifampin10aTreatment Outcome1 aDeps PD1 aNasser S1 aGuerra P1 aSimon M1 aBirshner RDC1 aRodrigues L00aAdverse effects from multi-drug therapy in leprosy: a Brazilian study.  uhttps://leprosyreview.org/article/78/3/21-6222  a216-220 v78  aInfolep Library - available3 a<p><b>INTRODUCTION: </b>The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil.</p><p><b>METHODS: </b>A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil. A specific and detailed protocol about side-effects was prepared and filled in from the patient records.</p><p><b>RESULTS: </b>One hundred ninety four patients' records were analysed looking for side-effects attributable to MDT. Side-effects were attributed to at least one MDT component in 88 (45%) patients and 85 had side-effects due to dapsone, 24 due to rifampicin and 18 due to clofazimine. 185 episodes were identified. The suspected drug was stopped in 47 out of 88 episodes (24% patients); 46 had dapsone stopped, 5 had rifampicin stopped and no-one had clofazimine stopped.</p><p><b>CONCLUSION: </b>Side-effects attributed to MDT is more frequent than previously described, resulting in interruption of treatment in many patients.</p>  a0305-7518